Exploring new cancer signaling pathways using viruses
Identification of Novel Oncogenic Signaling Pathways using Viral Perturbations
This study is looking into how certain viruses might change the way Merkel cell carcinoma, a rare and aggressive skin cancer, develops, with the hope that understanding these changes can lead to better treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10884342 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind Merkel cell carcinoma (MCC), a rare but aggressive skin cancer, by examining how viral infections can alter cancer signaling pathways. The study focuses on two types of MCC: virus-negative, which is linked to UV damage, and virus-positive, caused by viral DNA integration. By utilizing advanced tools and methodologies, the research aims to uncover the genetic differences and mutations associated with these cancers, potentially leading to better treatment strategies. Patients may benefit from insights gained that could improve understanding and management of various cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and young adults diagnosed with Merkel cell carcinoma or other related skin cancers.
Not a fit: Patients with non-skin-related cancers or those outside the age range of 0-21 may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and outcomes for patients with aggressive skin cancers.
How similar studies have performed: Other research has shown promising results in understanding cancer mechanisms through viral interactions, indicating potential for success in this approach.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Decaprio, James a. — Dana-Farber Cancer Inst
- Study coordinator: Decaprio, James a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.